2024 2030 China Genetic Engineering Drug Industry Supply and Demand Situation and Investment Opportunities Analysis Report
Publisher]: Zhongying Xinhe Research Network.
The content part has been deleted and detailed can be found in the full information published by Zhongying Xinhe Research Network! 】
Chapter 1 Overview of Genetically Engineered Drugs.
1.1 Basic introduction to genetically engineered drugs.
1.1.1 Definition of Genetically Engineered Drugs.
1.1.2 Efficacy of genetically engineered drugs.
1.1.3 Categories of genetically engineered drugs.
1.1.4. Production process of genetically engineered drugs.
1.2 Characteristics of the genetic engineering drug industry.
1.2.1 High technology.
1.2.2 High investment.
1.2.3 Long cycles.
1.2.4 High risk.
1.2.5 High returns.
Chapter 2 Development Environment of China's Genetically Engineered Drugs Industry from 2021 to 2023.
2.1 Policy environment.
2.1.1 Industry regulatory policies.
2.1.2. Specifications for the purchase and sale of drugs.
2.1.3. Development supportive policies.
2.1.4 Genetic policy.
2.1.5 Rare Disease Support**.
2.2 Economic Environment.
2.2.1 Macroeconomic overview.
2.2.2 Medical expenses.
2.2.3 Analysis of foreign economic relations.
2.2.4 Macroeconomic outlook.
2.3 Medical settings.
2.3.1 Medical and health resources.
2.3.2 Supply and demand of medical services.
2.3.3 Drug review.
2.3.4 Overview of infectious disease outbreaks.
Chapter 3 Analysis of the development of genetically ** drugs from 2021 to 2023.
3.1 Overview of the development of genes.
3.1.1 Definition of genes.
3.1.2 Genetic classification.
3.1.3 Genetic processes.
3.1.4. Gene ** industry chain.
3.2 2021-2023 analysis of the operation of the gene ** drug market.
3.2.1 Market development stage.
3.2.2 Drug approvals.
3.2.3 Project R&D progress.
3.2.4 Main clinical applications.
3.3 Status of CAR-T drug development, 2021-2023.
3.3.1 Brief introduction to CAR-T.
3.3.2 Product Availability.
3.3.3 Market sales volume.
3.3.4 Progress in drug development.
3.4 Development of nucleic acid drugs in 2021-2023.
3.4.1 Introduction to nucleic acid drugs.
3.4.2 Main technical routes.
3.4.3 Product research and development progress.
3.4.4 Mergers and acquisitions.
3.4.5 Development challenges and opportunities.
3.5 Analysis of the difficulties in the development of gene drugs.
3.5.1 **Fee Issues.
3.5.2 Drug regulatory issues.
3.5.3 Large-scale production challenges.
Chapter 4 Comprehensive Analysis of the Development of Recombinant Protein Drugs from 2021 to 2023.
4.1 Basic introduction of recombinant protein drugs.
4.1.1 Definition of recombinant protein drugs.
4.1.2 The history of recombinant protein drugs.
4.1.3 Drug classification and indication introduction.
4.2 Operation status of China's recombinant protein drug market from 2021 to 2023.
4.2.1 Product research and development progress.
4.2.2 Segment market share.
4.2.3 Market competition.
4.2.4 Market development potential.
4.3 Introduction of recombinant protein drugs of major companies.
4.3.1 Sinovac Pharmaceutical.
4.3.2 Northland.
4.3.3 Kinsey Pharmaceuticals.
4.3.4 Gan & Lee Pharmaceutical.
Chapter 5 2021-2023 China Key Recombinant Protein Drug Market Analysis.
5.1 Recombinant human insulin.
5.1.1 Main types and characteristics.
5.1.2 Market development scale.
5.1.3 Segment Status.
5.1.4. Market demand.
5.1.5 Competitive Landscape.
5.1.6 Market development potential.
5.2 Recombinant human growth hormone.
5.2.1 Basic product introduction.
5.2.2 Market development scale.
5.2.3 Market application.
5.2.4 Market competition pattern.
5.3 Recombinant human follicle-stimulating hormone.
5.3.1 Introduction to follicle-stimulating hormone.
5.3.2 Analysis of the industrial chain.
5.3.3 Market development drivers.
5.3.4. Market development scale.
5.3.5 Competitive Landscape.
5.3.6 Introduction of key enterprises.
5.4 Recombinant human interferon.
5.4.1 Main types of products.
5.4.2 Major clinical indications.
5.4.3. Characteristics of the technical level.
5.4.4. Market development scale.
5.4.5 Segment Market Share.
5.4.6 Competitive landscape.
5.5 Recombinant human erythropoietin.
5.5.1 Mechanism of action.
5.5.2 Product development process.
5.5.3. Market development scale.
5.5.4. Application market demand.
5.5.5 Competitive Landscape.
Chapter 6 Business Analysis of Key Enterprises in China's Genetic Engineering Drug Industry.
6.1 Beijing Northland Biotechnology Co., Ltd. ***
6.1.1. Overview of enterprise development.
1.1.1. Analysis of business benefits.
1.1.2 Business operation analysis.
1.1.3 Analysis of financial situation.
1.1.4. Core competitiveness analysis.
1.1.5. The company's development strategy.
1.1.6 Future prospects.
6.2 Anhui Anke Bioengineering (Group) Co., Ltd. ***
6.2.1. Overview of enterprise development.
6.2.2. Analysis of business benefits.
6.2.3 Business operation analysis.
6.2.4 Analysis of the financial situation.
6.2.5. Core competitiveness analysis.
6.2.6 The company's development strategy.
6.2.7 Future prospects.
6.3 Gan & Lee Pharmaceutical Co., Ltd. ***
6.3.1. Overview of enterprise development.
6.3.2. Analysis of business benefits.
6.3.3 Business operation analysis.
6.3.4 Analysis of the financial situation.
6.3.5. Core competitiveness analysis.
6.3.6 The company's development strategy.
6.3.7 Future prospects.
6.4 Beijing Sanyuan Gene Pharmaceutical Co., Ltd. ***
6.4.1. Overview of enterprise development.
6.4.2. Analysis of business benefits.
6.4.3 Business operation analysis.
6.4.4 Analysis of the financial situation.
6.4.5. Core competitiveness analysis.
6.4.6 The company's development strategy.
6.4.7 Future prospects.
6.5 Jiangsu Sihuan Biological Co., Ltd. ***
6.5.1. Overview of enterprise development.
6.5.2. Analysis of business benefits.
6.5.3 Business operation analysis.
6.5.4 Analysis of the financial situation.
6.5.5. Core competitiveness analysis.
6.5.6 The company's development strategy.
6.5.7 Future prospects.
6.6 Beijing Shuanglu Pharmaceutical Co., Ltd. ***
6.6.1. Overview of enterprise development.
6.6.2. Analysis of business benefits.
6.6.3 Business operation analysis.
6.6.4 Analysis of the financial situation.
6.6.5. Core competitiveness analysis.
6.6.6 The company's development strategy.
6.6.7 Future prospects.
Chapter 7 2021-2023 Investment Analysis of Genetic Engineering Drug Industry.
7.1 Investment barriers in the genetic engineering drug industry.
7.1.1 Technical barriers.
7.1.2 Financial barriers.
7.1.3 Policy barriers.
7.2 Investment risk warning in the genetic engineering drug industry.
7.2.1 Technical Risks.
7.2.2 Talent Risk.
7.2.3 Policy risk.
7.2.4 Competitive Risk.
7.2.5 Legal Risks.
7.3 Investment and financing dynamics of the genetic engineering drug industry.
7.3.1. Strategic mergers and acquisitions of international leading enterprises.
7.3.2. Investment and financing dynamics of domestic enterprises.
7.3.3 IPO fundraising dynamics of domestic enterprises.
Chapter 8 Development Trends and Prospects of China's Genetic Engineering Drugs Market.
8.1 The development trend of China's genetic engineering drug market.
8.1.1 **Become an important entrant.
8.1.2 Enterprises accelerate the market seizure.
8.1.3. The substitution of domestic drugs is accelerating.
8.1.4 CDMO has become a new growth point.
8.2 Outlook for China's genetically engineered drug industry.
8.2.1 Gene** has reached a commercial inflection point.
8.2.2. Policies promote the steady development of the industry.
8.2.3. Enhance innovation ability and promote development.
8.2.4. Improving drug conditions are driving the market.
8.2.5. Broadening financing channels is conducive to development.
Table of Contents of Charts. Diagram Production process of genetically engineered drugs.
Chart The main regulatory authorities of the genetic engineering drug industry and their functions.
Chart Supporting policies for the development of the genetic engineering drug industry.
Chart Summary of China's gene**-related policies in 2023.
Chart: Summary of policies and regulations related to rare diseases in China.
Chart GDP and growth rate in 2023.
Chart: Proportion of added value of the three industries to GDP in 2023.
Chart China's preliminary GDP accounting data for 2022.
Chart Preliminary accounting data of domestic GDP in 2023.
Chart 2023 Hospital Patient Outpatient and Inpatient Expenses.
Chart Outpatient and inpatient expenses for patients in primary healthcare facilities, 2023.
Figure 11 Total imports and exports of goods in 2023.
Exhibit 12 Total imports and exports of goods and their growth rate in 2023.
Figure 13 Volume, value and growth rate of exports of major commodities in 2023.
Exhibit 14 Imports of major commodities in 2023 in terms of volume, value and growth rate.
Figure 15 Imports and exports of goods to major countries and regions in 2023 amount, growth rate and proportion.
Figure Number of medical and health institutions nationwide in 2023.
Figure Number of medical and health institutions and beds in China in 2023.
Chart: The number and growth rate of beds in medical and health institutions across the country in 2023.
Figure Number of health personnel in the country in 2023.
Figure Number of personnel in various medical and health institutions in China in 2023 (10,000 people).
Chart: The number of diagnoses and treatments and the growth rate of medical and health institutions nationwide in 2023.
Figure 2023 National Medical Service Workload.
Figure The number and growth rate of hospitalizations in medical and health institutions in China in 2030.
Figure 2023 workload of hospital physicians.
Chart Hospital bed usage in 2023.
Chart Acceptance of registration applications for various types of drugs in 2023.
Chart Acceptance of registration applications for various types of drugs requiring technical review in 2023.
Figure Number of reported cases and deaths of Class A and B infectious diseases in China in 2023.
Figure Number of reported cases and deaths of Class C infectious diseases in China in 2023.
Chart Genomic type.
Diagram Gene ** process.
Chart: The core link of the gene ** industry chain.
Chart Key enterprises of culture medium in China.
Chart Stages of development of genes.
Chart As of 2023, there are approved genetic** drugs in the world (1).
Chart As of 2023, there are approved genetics** drugs in the world (2).
Figure Number of industry-led clinical trials in 2023.
Figure Progress of clinical trials of genetics** in China as of 2023 (1).
Chart Progress of clinical trials of genetics in China as of 2023 (2).
Chart Genetic** clinical trial indication areas as of 2023.
Chart CAR-T Technology Roadmap.
Chart As of the end of 2022, the FDA approved CAR-T drugs and their indications.
Chart 2023 CAR-T drug sales.
Chart: Cumulative number of registered CAR-T clinical trial projects in China and the United States in 2023.
Figure The history of nucleic acid drug research and development.
Chart As of 2023, FDA approved ASO drugs and their indications.
Figure 2023 FDA approved siRNA drugs and their indications.
Chart 2023 Transactions and M&A cases in the field of nucleic acid drugs.
Chart Classification and indications of recombinant protein drugs.
Chart Recombinant protein drugs and corresponding manufacturers marketed in China (1).
Chart Recombinant protein drugs and corresponding manufacturers listed in China (2).
Chart Recombinant protein drugs and corresponding manufacturers marketed in China (3).
Chart China's recombinant protein market share.
Chart Basic situation of Sinovac Pharmaceutical's recombinant protein drugs.
Chart Sinovac Pharmaceutical's recombinant human erythropoietin injection (CHO cell) product profile.
Figure Sinovac Pharmaceutical's recombinant human interferon 1b for injection product overview.
Chart Overview of Sinovac Pharmaceutical's Recombinant Human Granulocyte Stimulating Factor Injection Solution.
Chart Basic situation of recombinant protein drugs in Northland.
Chart: Basic situation of recombinant protein drugs of Kinsey Pharmaceutical.
Chart: Basic situation of recombinant protein drugs (recombinant insulin) of Gan & Lee Pharmaceutical.
Chart Insulin development and its various categories.
Chart Comparison of the effects of various insulin analogues.
Chart Comparison of human insulin analogues by premix.
Chart China's insulin sales and growth rate in 2023.
Chart 2023 China Recombinant Human Insulin Market Segment Structure.
Chart: Competitive landscape of terminal chemical drugs insulin and similar drugs in China's public medical institutions in 2023.
Chart Major insulin products and corresponding manufacturers in the Chinese market.
Chart Classification of short stature**.
Figure History of growth hormone development.
Chart Comparison of different dosage forms of growth hormone.
Chart 2023 sales and growth rate of growth hormone in China's sample hospitals.
Chart Age structure of growth hormone users in the United States.
Figure Proportion of off-label use of growth hormone in the United States.
Chart Comparison of approvals for growth hormone indications in China and the United States.
Chart Growth hormone dosage forms for the Chinese market.
Chart China's growth hormone market share in 2023.
Chart: Growth hormone under development by Chinese companies.
Chart Types of assisted reproductive drugs.
Figure Difference between urinary and recombinant follicle-stimulating hormone.
Chart Recombinant follicle-stimulating hormone benefits.
Chart Recombinant follicle-stimulating hormone industry chain in China.
Figure Infertility rate in China in 2023.
Chart Recombinant human follicle-stimulating hormone market size and market share in 2023.
Chart Recombinant follicle-stimulating hormone and urinary follicle-stimulating hormone products have been launched in China.
Chart The competitive landscape of the follicle-stimulating hormone market in the Chinese market in 2023.
Chart Status of recombinant follicle-stimulating hormone products under development in China as of 2023.
Chart Short-acting and long-acting interferon products marketed in China.
Chart Comparison of long-acting and short-acting interferon indications.
Chart Sales of short-acting recombinant human interferon in China in 2023.
Chart Sales of long-acting recombinant human interferon in China in 2023.
Chart 2023 Market share of sales of each subtype of interferon injection in China.
Chart Sales value of different dosage forms of short-acting interferon in China in 2023.
Chart Comparison of China's market share by dosage form in 2023.
Figure Summary of manufacturers of recombinant human interferon preparations as of 2023.
Chart 2023 Recombinant Human Interferon Market Landscape in Sample Hospitals.
Chart China recombinant human erythropoietin market size in 2023.
Chart As of 2023, the main manufacturers of recombinant human erythropoietin in China.
Chart 2019-2023 Beijing Northland Biotechnology Co., Ltd.*** total assets and net assets scale.
Chart 2019-2023 Beijing Northland Biotechnology Co., Ltd.*** operating income and growth rate.
Chart 2019-2023 Beijing Northland Biotechnology Co., Ltd. *** net profit and growth rate.
Chart 2023 Beijing Northland Biotechnology Co., Ltd.*** main business by industry.
Chart 2023 Beijing Northland Biotechnology Co., Ltd.***Main business by region.
Chart 2019-2023 Beijing Northland Biotechnology Co., Ltd.*** operating profit and operating profit margin.
Chart 2019-2023 Beijing Northland Biotechnology Shares*** Return on Net Assets.
Chart 2019-2023 Beijing Northland Biotechnology Shares*** Short-term Solvency Indicator.
Chart 2019-2023 Beijing Northland Biotechnology Co., Ltd.*** asset-liability ratio level.
Chart 2019-2023 Beijing Northland Biotechnology Co., Ltd. *** Operational Capability Indicators.
Chart 2019-2023 Anhui Anke Bioengineering (Group) Co., Ltd.*** total assets and net assets scale.
Chart 2019-2023 Anhui Anke Bioengineering (Group) Co., Ltd.*** operating income and growth rate.
Chart 2019-2023 Anhui Anke Bioengineering (Group) Co., Ltd. *** net profit and growth rate.
Chart 2023 Anhui Anke Bioengineering (Group) Co., Ltd.*** main business by industry.
Chart 2023 Anhui Anke Bioengineering (Group) Co., Ltd.*** main business by region.
Chart 2019-2023 Anhui Anke Bioengineering (Group) Co., Ltd.*** operating profit and operating profit margin.
Chart 2019-2023 Anhui Anke Bioengineering (Group) shares*** return on net assets.
Chart 2019-2023 Anhui Anke Bioengineering (Group) shares *** short-term solvency index.
Chart 2019-2023 Anhui Anke Bioengineering (Group) shares*** asset-liability ratio level.
Chart 2019-2023 Anhui Anke Bioengineering (Group) Co., Ltd. *** operating capacity indicators.
Chart 2019-2023 Gan & Lee Pharmaceutical Co., Ltd.*** total assets and net assets.
Chart 2019-2023 Gan & Lee Pharmaceutical Co., Ltd.*** operating income and growth rate.
Chart 2019-2023 Gan & Lee Pharmaceutical Co., Ltd.*** net profit and growth rate.
Chart 2023 Gan & Lee Pharmaceutical Co., Ltd.*** main business by industry.
Chart 2023 Gan & Lee Pharmaceutical Co., Ltd.*** main business by region.
Chart 2019-2023 Gan & Lee Pharmaceutical Co., Ltd.*** operating profit and operating profit margin.
Chart 2019-2023 Gan & Lee Pharmaceutical shares*** return on net assets.
Chart 2019-2023 Gan & Lee Pharmaceutical Co., Ltd. *** short-term solvency indicator.
Chart 2019-2023 Gan & Lee Pharmaceutical Co., Ltd.*** asset-liability ratio level.
Chart 2019-2023 Gan & Lee Pharmaceutical Co., Ltd. *** operating capacity indicators.
Chart 2019-2023 total assets and net assets of Sanyuan Gene Pharmaceutical Co., Ltd.
Chart 2019-2023 Sanyuan Gene Pharmaceutical Co., Ltd.*** operating income and growth rate.
Chart 2019-2023 net profit and growth rate of Sanyuan Gene Pharmaceutical Co., Ltd.
Chart 2023 Sanyuan Gene Pharmaceutical Co., Ltd.*** main business by industry.
Chart 2023 Sanyuan Gene Pharmaceutical Co., Ltd.*** main business by region.
Chart 2019-2023 Sanyuan Gene Pharmaceutical Co., Ltd.*** operating profit and operating profit margin.
Chart 2019-2023 return on net assets of Sanyuan Gene Pharmaceutical Co., Ltd.
Chart 2019-2023 Sanyuan Gene Pharmaceutical Co., Ltd.*** short-term solvency index.
Chart 2019-2023 Ternary Gene Pharmaceutical Co., Ltd.*** asset-liability ratio level.
Chart 2019-2023 Ternary Gene Pharmaceutical Co., Ltd. *** operating capacity indicators.
Chart 2019-2023 Jiangsu Sihuan Biotechnology Co., Ltd.*** total assets and net assets scale.
Chart 2019-2023 Jiangsu Sihuan Biotechnology Co., Ltd.*** operating income and growth rate.
Chart 2019-2023 Jiangsu Sihuan Biotechnology Co., Ltd. *** net profit and growth rate.
Chart 2023 Jiangsu Sihuan Biotechnology Co., Ltd.*** main business by industry.
Chart 2023 Jiangsu Sihuan Biotechnology Co., Ltd.*** Main business by region.
Chart 2019-2023 Jiangsu Sihuan Biotech Co., Ltd.*** operating profit and operating profit margin.
Chart 2019-2023 Jiangsu Sihuan Biotech shares*** return on net assets.
Chart 2019-2023 Jiangsu Sihuan Biotechnology Co., Ltd. *** short-term solvency index.
Chart 2019-2023 Jiangsu Sihuan Biotech shares*** asset-liability ratio level.
Chart 2019-2023 Jiangsu Sihuan Biotechnology Co., Ltd. *** operating capacity indicators.
Chart 2019-2023 Beijing Shuanglu Pharmaceutical Co., Ltd.*** total assets and net assets scale.
Chart 2019-2023 Beijing Shuanglu Pharmaceutical Co., Ltd.*** operating income and growth rate.
Chart 2019-2023 Beijing Shuanglu Pharmaceutical Co., Ltd. *** net profit and growth rate.
Chart 2023 Beijing Shuanglu Pharmaceutical Co., Ltd.*** main business by industry.
Chart 2023 Beijing Shuanglu Pharmaceutical Co., Ltd.*** main business by region.
Chart 2019-2023 Beijing Shuanglu Pharmaceutical Co., Ltd.*** operating profit and operating profit margin.
Chart 2019-2023 return on net assets of Beijing Shuanglu Pharmaceutical Co., Ltd.
Chart 2019-2023 Beijing Shuanglu Pharmaceutical Co., Ltd. *** short-term solvency index.
Chart 2019-2023 Beijing Shuanglu Pharmaceutical Co., Ltd.*** asset-liability ratio level.
Chart 2019-2023 Beijing Shuanglu Pharmaceutical Co., Ltd. *** operating capacity indicators.
Figure The main contaminants involved in the bioengineered drug development process.